Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.

Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.

<h4>Background</h4>Transforming growth factor beta (TGF-β) signalling is involved in the development of hepatocellular carcinoma (HCC). We followed changes in biomarkers during treatment of patients with HCC with the TGF-βRI/ALK5 inhibitor galunisertib.<h4>Methods</h4>This ph...

Full description

Bibliographic Details
Main Authors: Gianluigi Giannelli, Armando Santoro, Robin K Kelley, Ed Gane, Valerie Paradis, Ann Cleverly, Claire Smith, Shawn T Estrem, Michael Man, Shuaicheng Wang, Michael M Lahn, Eric Raymond, Karim A Benhadji, Sandrine Faivre
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0222259

Internet

https://doi.org/10.1371/journal.pone.0222259

Similar Items